-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 08-30-2026 TO 09-05-2026
I’m excited to announce the release of my latest FREE bio tech stock catalyst report for the upcoming week. This new FREE stock report highlights bio tech companies that have an important upcoming event and an expected price move of 20 percent up or down ($ +/- 20%) to help you make informed market decisions.…
-
Stepping Into the Future: CovationBio Unveils Bio-Based Sports Insoles
Innovation Meets Performance The materials industry is taking a major step toward sustainability. CovationBio has announced the debut of its groundbreaking sports insole, marking a significant milestone as the first non-food, bio-based sports insole to hit the market. This innovation will be officially showcased at the upcoming NW Materials Show. Why This Matters for the…
-
New Hope for ALS: Cellenkos Receives FDA Fast Track Designation for CK0803
A Breakthrough for ALS Treatment The fight against Amyotrophic Lateral Sclerosis (ALS) has reached a significant milestone. Cellenkos, a clinical-stage biotechnology company, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to their investigational therapy, CK0803. What is CK0803? CK0803 is an innovative allogeneic cell therapy derived from umbilical…
-
BeOne Medicines Announces U.S FDA Approval for Tevimbra-Based Regimen for First-Line HER2+ GEA
NASDAQ: $ONC SAN CARLOS, Calif.–(BUSINESS WIRE) Aug 25, 2026 — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics… Source: Read More
-
Typewriter Therapeutics Emerges from Stealth with $56 Million to Pioneer In Vivo CAR-T Medicines
A New Era for Cell Therapy The landscape of oncology treatment is shifting. Typewriter Therapeutics has officially emerged from stealth mode, announcing a significant $56 million Series A financing round. This milestone marks a bold step forward in the development of in vivo CAR-T medicines, aiming to make advanced cell therapies more accessible and effective.…
-
New Hope for Alpha-gal Syndrome: NIH Researchers Discover Rare Antibodies
A Breakthrough in Allergy Research For those living with Alpha-gal syndrome (AGS)—a life-altering condition that triggers severe allergic reactions to red meat and other products derived from mammals—the path forward may be getting clearer. Researchers at the National Institutes of Health (NIH) have recently identified a unique set of rare antibodies that could change how…
-
Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine
NYSE: $PFE A New Development in COVID-19 Prevention As we continue to navigate the evolving landscape of respiratory health, the U.S. Food and Drug Administration (FDA) has taken a significant step forward. Pfizer and BioNTech have officially received FDA approval for their updated Comirnaty COVID-19 vaccine, specifically adapted to target more recent circulating variants. What…
-
Shoulder Innovations Set to Present at Morgan Stanley 24th Annual Healthcare Conference
NYSE: $SI Strategic Participation in Healthcare Industry Leadership Shoulder Innovations, a company dedicated to advancing the field of shoulder replacement technology, has officially announced its participation in the prestigious Morgan Stanley 24th Annual Healthcare Conference. This event serves as a significant platform for industry leaders, investors, and innovators to discuss the future of medical technology.…
-
New Hope in MS Treatment: Novartis Reports Positive Results for Remibrutinib
A Potential Breakthrough for Multiple Sclerosis Novartis has recently shared promising clinical trial data regarding remibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor currently being studied for the treatment of relapsing multiple sclerosis (RMS). The latest findings highlight the drug’s potential to significantly improve outcomes for patients living with this challenging condition. Significant Reduction in…
-
A New Treatment Option: FDA Approves Stelara for Pediatric Ulcerative Colitis
Expanding Care for Young Patients Managing ulcerative colitis as a child or teenager presents unique challenges. Recently, the medical community reached a significant milestone in pediatric care. The FDA has officially approved Stelara (ustekinumab) for the treatment of pediatric patients aged 6 years and older who are suffering from moderately to severely active ulcerative colitis.…
-
Mark Your Calendars: Research Solutions Sets Q4 and Fiscal Year 2026 Earnings Date
NASDAQ: $RSSS Upcoming Financial Reporting Research Solutions, Inc. (NASDAQ: RSSS) has officially announced that it will release its financial results for the fourth quarter and fiscal year ended June 30, 2026. Investors and stakeholders should mark their calendars for the morning of Wednesday, September 9, 2026, when the company plans to share its performance metrics.…
-
BioNTech Shares Update on Autogene Cevumeran Phase 2 Trial for Colorectal Cancer
NASDAQ: $BNTX An Important Update in Precision Oncology BioNTech SE has recently provided a clinical update regarding its Phase 2 trial of autogene cevumeran (BNT122), an investigational individualized mRNA-based cancer vaccine. The study focuses on patients with resected colorectal cancer who are at high risk of recurrence. Understanding the Trial Focus The Phase 2 trial…
-
Moderna Receives U.S. FDA Approval for Updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 Vaccines
NASDAQ: $MRNA CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for… Source: Read More
-
Genomma Lab Internacional Secures Strategic Long-Term Debt Financing
Strengthening Financial Foundations Genomma Lab Internacional, a prominent player in the pharmaceutical and personal care industry, has officially announced the completion of a significant long-term debt transaction. This strategic financial maneuver is designed to bolster the company’s capital structure and support its ongoing operational objectives. Key Details of the Transaction The company has utilized this…
-
Novo Nordisk Provides Update on ZEUS Phase 3 Trial for Ziltivekimab
A New Approach to Cardiovascular Risk Novo Nordisk recently released an update regarding the ZEUS Phase 3 clinical trial, which is investigating the efficacy of ziltivekimab. This trial focuses on patients suffering from both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), a population with significant unmet medical needs. Understanding the ZEUS Trial The…
-
A New Treatment Milestone: FDA Approves Besremi for Essential Thrombocythemia
Expanding Options for Patients There is promising news for adults living with Essential Thrombocythemia (ET). The U.S. Food and Drug Administration (FDA) has officially approved Besremi (ropeginterferon alfa-2b-njft) as a treatment option for adults diagnosed with this rare blood disorder. This approval marks a significant development in the therapeutic landscape for those managing ET. Understanding…
-
A New Hope for Peanut Allergy Sufferers: FDA Grants Fast Track Designation to PVX108
Revolutionizing Peanut Allergy Treatment For millions of people living with a peanut allergy, even accidental exposure can cause life-threatening reactions. Recently, the biotechnology company Aravax reached a major milestone in the fight to change this reality. The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to the company’s lead investigational product,…
-
A Major Milestone: FDA Approves Mounjaro (Tirzepatide) for Cardiovascular Risk Reduction
NYSE: $LLY New Hope for Heart Health in Type 2 Diabetes In a significant development for patients living with type 2 diabetes, the FDA has approved an updated indication for Mounjaro (tirzepatide). While widely recognized for its efficacy in glycemic control, the medication is now officially indicated to help reduce the risk of major adverse…
-
Navigating the Future of Preclinical Oncology: Choosing the Right Xenograft Model
Advancing Cancer Research Through Model Selection In the rapidly evolving field of oncology drug discovery, selecting the appropriate preclinical model is more than a technical decision—it is a critical step that determines the translational success of a therapeutic candidate. A recent release highlights the vital importance of standardization and strategic selection across the diverse landscape…
-
Could Zepbound Be the Key to Lower Healthcare Costs for Adults Over 55?
NYSE: $LLY New Real-World Data on Obesity Management A recent observational study has shed new light on the long-term impact of Zepbound (tirzepatide) on healthcare economics. While the medication is widely recognized for its efficacy in weight management, new data suggests that for adults over the age of 55, it may lead to significant reductions…
-
The Future of Medicine: Why the Oligonucleotide CDMO Market is Poised for Massive Growth
A New Era in Therapeutic Innovation The pharmaceutical landscape is shifting rapidly, and at the heart of this transformation is the rise of oligonucleotide therapeutics. According to a recent report by MarketsandMarkets, the global oligonucleotide CDMO market is projected to reach a valuation of $11.14 billion by 2031, growing at a significant CAGR during the…
-
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NASDAQ: $NKTR SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar’s Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common… Source: Read More
-
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
NASDAQ: $CTMX SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted… Source: Read More
-
A Breakthrough for Polycythemia Vera: FDA Approves Mimrylo (rusfertide)
NYSE: $TAK A New Chapter in Blood Disorder Management For patients living with Polycythemia Vera (PV), managing hematocrit levels and the risks of blood clots has long been a challenging daily reality. Recently, the medical landscape for this chronic condition saw a significant shift with the FDA approval of Mimrylo (rusfertide). Understanding Mimrylo Mimrylo is…